GlobeNewswire: Hepion Pharmaceuticals, Inc. Contains the last 10 of 159 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T21:30:58ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/06/2841417/0/en/Hepion-Pharmaceuticals-Strengthens-Board-of-Directors-with-Appointment-of-Michael-Purcell.html?f=22&fvtc=4&fvtv=32003Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell2024-03-06T13:30:00Z<![CDATA[EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company’s Board of Directors, effective March 5, 2024.]]>https://www.globenewswire.com/news-release/2024/02/16/2830728/0/en/Hepion-Pharmaceuticals-Announces-Exercise-of-Warrants-for-Approximately-2-0-Million-Aggregate-Gross-Proceeds.html?f=22&fvtc=4&fvtv=32003Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds2024-02-16T13:00:00Z<![CDATA[EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares of Hepion common stock for gross proceeds to the Company of approximately $2.0 million.]]>https://www.globenewswire.com/news-release/2024/01/03/2803663/0/en/Hepion-Pharmaceuticals-to-Present-at-NASH-TAG-2024.html?f=22&fvtc=4&fvtv=32003Hepion Pharmaceuticals to Present at NASH-TAG 20242024-01-03T22:15:00Z<![CDATA[EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the 2024 NASH-TAG Conference, which is being held January 4-6, 2024, in Park City, Utah.]]>https://www.globenewswire.com/news-release/2023/12/07/2792459/0/en/Hepion-Pharmaceuticals-Announces-Restructuring-Plan-to-Enhance-Shareholder-Value-and-Management-Changes.html?f=22&fvtc=4&fvtv=32003Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes2023-12-07T13:00:00Z<![CDATA[Restructuring program purpose is to preserve capital and optimize clinical development program]]>https://www.globenewswire.com/news-release/2023/11/28/2787371/0/en/Hepion-Pharmaceuticals-to-Present-at-the-7th-Obesity-NASH-Drug-Development-Summit.html?f=22&fvtc=4&fvtv=32003Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit2023-11-28T21:15:00Z<![CDATA[EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it will present at the 7th Obesity & NASH Drug Development Summit taking place November 27 – 29, 2023 in Boston.]]>https://www.globenewswire.com/news-release/2023/11/13/2779461/0/en/Hepion-Pharmaceuticals-Announces-Major-Reductions-in-Liver-Stiffness-with-Rencofilstat-Treatment-in-17-week-Phase-2-Study-of-Advanced-F3-MASH-Liver-Disease.html?f=22&fvtc=4&fvtv=32003Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease 2023-11-13T21:05:00Z<![CDATA[- Demonstrated improvements among best reported of fibrosis-reducing compounds -]]>noneFibroscan Liver Stiffness Absolute Change from Baseline (kPa)https://www.globenewswire.com/news-release/2023/11/10/2778336/0/en/Hepion-Pharmaceuticals-Schedules-Conference-Call-to-Review-Additional-Efficacy-Data-from-Phase-2-ALTITUDE-NASH-Liver-Function-Trial-of-Rencofilstat.html?f=22&fvtc=4&fvtv=32003Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat2023-11-10T13:50:00Z<![CDATA[Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023 Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023]]>https://www.globenewswire.com/news-release/2023/10/25/2766519/0/en/Hepion-Pharmaceuticals-Rencofilstat-Demonstrates-Anti-Cancer-Activity-in-Hepatitis-C-Associated-Cancer-Model.html?f=22&fvtc=4&fvtv=32003Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model2023-10-25T12:30:00Z<![CDATA[- Rencofilstat, but not sofosbuvir or velpatasvir, significantly suppressed tumor growth - - Rencofilstat, but not sofosbuvir or velpatasvir, significantly suppressed tumor growth -]]>https://www.globenewswire.com/news-release/2023/09/29/2751947/0/en/Hepion-Pharmaceuticals-Announces-5-0-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement-Priced-At-The-Market-under-Nasdaq-Rules.html?f=22&fvtc=4&fvtv=32003Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules2023-09-29T12:00:00Z<![CDATA[EDISON, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it has entered into a securities purchase agreement with a healthcare-focused institutional investor for the purchase and sale of 980,393 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.10 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, Hepion will issue to the investor unregistered Series A Warrants to purchase up to an aggregate of 980,393 shares of common stock and Series B Warrants to purchase up to an aggregate of 980,393 shares of common stock. The Series A and Series B Warrants will have an exercise price of $4.85 per share, will be exercisable immediately following the date of issuance and will expire in five years and one and a half years, respectively. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2023/09/21/2747653/0/en/Hepion-Pharmaceuticals-to-Participate-in-2023-Cantor-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=32003Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference2023-09-21T20:05:00Z<![CDATA[EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that its Chief Executive Officer, Robert Foster, PharmD, PhD, will participate in a panel discussion during the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 9:45 a.m. ET in NYC.]]>